Search Results - "Bergeron, Jonathan"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Dietary R, S‐1,3‐butanediol diacetoacetate reduces body weight and adiposity in obese mice fed a high‐fat diet by Davis, Rachel A. H., Deemer, Sarah E., Bergeron, Jonathan M., Little, Jason T., Warren, Jonathan L., Fisher, Gordon, Smith, Daniel L., Fontaine, Kevin R., Dickinson, Stephanie L., Allison, David B., Plaisance, Eric P.

    Published in The FASEB journal (01-02-2019)
    “…ABSTRACT The dietary R‐3‐hydroxybutyrate‐R‐1,3‐butanediol monoester increases resting energy expenditure (REE) and markers of brown and white adipose…”
    Get full text
    Journal Article
  2. 2

    Synthesis and crystal structures of 2-(ferrocenyl-carbon-yl)benzoic acid and 3-ferrocenylphthalide by Pokharel, Uttam R, Bergeron, Jonathan T, Fronczek, Frank R

    “…The title compounds, 2-(ferrocenylcarbon-yl)benzoic acid, [Fe(C H )(C H O )], , and 3-ferrocenylphthalide [systematic name: 3-ferrocenyl-2-benzo-furan-1(3…”
    Get full text
    Journal Article
  3. 3

    Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials by Mayer-Hamblett, Nicole, Russell, Renee, Donaldson, Scott H, Sawicki, Gregory S, Odem-Davis, Katherine, Rosenbluth, Daniel, Taylor-Cousar, Jennifer L, Goss, Christopher H, Clancy, John Paul, O'Sullivan, Brian P, Berlinski, Ariel, Millard, Susan L, Omlor, Gregory, Wyatt, Colby A, Moffett, Kathryn, Kloster, Margaret, Chapdu, Claire, VanDalfsen, Jill, Mead, Anna, Seidel, Kathy, Couture, Laurel, Case, Brooke Zappone, Au, Wendy, Olander, Amber, VanHousen, Lisya, Parrish, Michelle, Head, Jillian, Carey, Jessica, Lysinger, Jerimiah, Virella-Lowell, Isabel, Brown, Perry, Godusevic, Lejla, Sweet, Julie, Donaldson, Scott, Szentpetery, Sylvia, Tharrington, Erica, Jain, Manu, McPhail, Gary, McBennett, Kimberly, Weaver, Dave, Sharma, Preeti, Jones, Amy, Cross, Mary, Mukadam, Zubin, Finto, Jill, Schultz, Karen, Graff, Gavin, Thompson, Misty, Teresi, Mary, Schaeffer, David, Mermis, Joel, Scott, Lawrence, Escobar, Hugo, O'Sullivan, Brian, Danov, Zoran, Turbeville, Kat, Marra, Bridget, Morton, Ronald, Dondlinger, Nicole, Biller, Julie, Billings, Joanne, Balaji, Priya, Griffith, Rebecca, Martinez, Nancy, Hussain, Sabiha, Guzman, Catalina, DeCelie-Germana, Joan, Galvin, Susan, Falgout, Nicole, Demarco, Teresa, DiMango, Emily, Ycaza, Maria, Tirakitsoontorn, Pornchai, Layish, Daniel, Wooldridge, Sherry, Milla, Carlos, Spano, Jacquelyn, Elidemir, Okan, Scott, Ashley, Alam, Sarah, Dorgan, Daniel, Weiner, Daniel, Renna, Harmony, Wyatt, Colby, Stone, Anne, Liou, Theodore, Akong, Kathryn, Gil, Marissa, Singer, Jonathan, Moreno, Courtney, Gambol, Teresa, Milton, Joan, Hodge, Diana, Fortner, Christopher, Forell, Mary, Patel, Kapil, Daines, Cori, Ryan, Elizabeth, Powell, Kay, Polineni, Deepika

    Published in The lancet respiratory medicine (01-04-2023)
    “…Reducing treatment burden is a priority for people with cystic fibrosis, whose health has benefited from using new modulators that substantially increase CFTR…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study by Plaisance, Eric P., Bergeron, Jonathan M., Bolyard, Mickey L., Hathorne, Heather Y., Graziano, Christina M., Hartzes, Anastasia, Genschmer, Kristopher R., Alvarez, Jessica A., Goss, Amy M., Gaggar, Amit, Fontaine, Kevin R.

    Published in Nutrients (19-11-2024)
    “…Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have greatly improved outcomes in persons with CF (pwCF); however, there is…”
    Get full text
    Journal Article
  6. 6

    Pharmacokinetic variability of CFTR modulators from standard and alternative regimens by Rose, Natalie R., Chalamalla, Ashritha R., Garcia, Bryan A., Krick, Stefanie, Bergeron, Jonathan, Sadeghi, Hossein, Schellhase, Dennis E., Ryan, Kevin J., Dowell, Alexander E., Acosta, Edward P., Guimbellot, Jennifer S.

    Published in Pulmonary pharmacology & therapeutics (01-09-2024)
    “…Elexacaftor, tezacaftor, ivacaftor (ETI) is a CFTR modulator combination approved for use in ∼90 % of people with cystic fibrosis (pwCF) over 2 years old…”
    Get full text
    Journal Article
  7. 7